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Background. Staphylococcus aureus is the most common cause of endovascular infections. The staphylococcal
accessory regulator A locus (sarA) is a major virulence determinant that may potentially impact methicillin-resistant
S. aureus (MRSA) persistence in such infections via its inﬂuence on bioﬁlm formation.
Methods. Two healthcare-associated MRSA isolates from patients with persistent bacteremia and 2 prototypical
community-acquired MRSA strains, as well as their respective isogenic sarA mutants, were studied for in vitro bio-
ﬁlm formation, ﬁbronectin-binding capacity, autolysis, and protease and nuclease activities. These assays were done
in the presence or absence of sub–minimum inhibitory concentrations (MICs) of vancomycin. In addition, these
strain pairs were compared for intrinsic virulence and responses to vancomycin therapy in experimental infective
endocarditis, a prototypical bioﬁlm model.
Results. All sarA mutants displayed signiﬁcantly reduced bioﬁlm formation and binding to ﬁbronectin but
increased protease production in vitro, compared with their respective parental strains. Interestingly, exposure to
sub-MICs of vancomycin signiﬁcantly promoted bioﬁlm formation and ﬁbronectin-binding in parental strains
but not in sarA mutants. In addition, all sarA mutants became exquisitely susceptible to vancomycin therapy, com-
pared with their respective parental strains, in the infective endocarditis model.
Conclusions. These observations suggest that sarA activation is important in persistent MRSA endovascular
infection, potentially in the setting of bioﬁlm formation.
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Staphylococcus aureus is the most common cause of en-
dovascular infections, including infective endocarditis
syndromes, which are associated with high morbidity
and mortality [1]. The increase in prevalence of methi-
cillin-resistant S. aureus (MRSA) strains in such
infections and the relatively high rates of vancomycin
clinical failures in these syndromes caused by MRSA
strains whose vancomycin minimum inhibitory con-
centrations (MICs) fall within the susceptible range
(ie, ≤2 μg/mL) have further complicated the manage-
ment of these patients [2]. In addition, MRSA is a
predominant cause of healthcare-associated (HA) in-
fections [3].However, life-threatening infections caused
by community-acquired MRSA (CA-MRSA) in other-
wise healthy people outside of healthcare settings have
recently reached epidemic proportions globally [4].
The pathogenesis of S. aureus is complex and in-
volves the coordinate expression of multiple gene prod-
ucts, including surface adhesins, exoproteins, and
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toxins. Of note, many staphylococcal virulence factors are con-
trolled by a major regulatory locus called staphylococcal acces-
sory regulator A (sarA) [5]. The sarA locus consists of 3
overlapping transcripts, driven by 3 distinct promoters: P1,
P3, and P2. These DNA-binding proteins bind to AT-rich in-
verted repeat or palindromic sequences on respective target pro-
moters to control the expression of multiple genes [5].
Importantly, laboratory-derived sarA mutants have exhibited
diminished virulence in infection models, including infective
endocarditis, osteomyelitis, and arthritis [6, 7].
Bioﬁlm formation plays a critical role in the development of
MRSA endovascular infections [8]. Treatment of these infec-
tions has become challenging because organisms within the bi-
oﬁlm are signiﬁcantly more resistant to antimicrobial agents, as
well as to clearance by the host defense system [9]. In addition,
recent studies suggest that sublethal doses of selected antibiotics
(eg, vancomycin) can induce bioﬁlm formation in MRSA
strains [10]. In this regard, SarA is an important positive regu-
lator of bioﬁlm development, in part because of its repressive
activity on protease production [11–13]. To our knowledge,
this study is the ﬁrst to examine the impact of vancomycin on
sarA-mediated bioﬁlm formation in MRSA in vitro, as well as in
vivo, in terms of intrinsic virulence and treatment outcomes in
endovascular infections.
MATERIALS AND METHODS
MRSA Strains
Two HA-MRSA isolates, selected from a multinational clini-
cal trial, were collected from patients demonstrating MRSA-
positive blood cultures for ≥14 days despite receiving antibiotics
to which the isolates were susceptible in vitro (Table 1) [16, 18].
In addition, 2 prototypical CA-MRSA strains, MW2 (USA400,
reported to cause fatal infections in children [19]) and JE2
(LAC, USA300 derivative that was cured of its three plasmids,
obtained from the Network on Antimicrobial Resistance in
Staphylococcus aureus) were also chosen for this study. A site-
speciﬁc mutant was obtained by transducing the sarA::
Tn917LTV1 mutation from strain ALC637 (Newman, sarA:
Tn917LTV1) [14] into strain 324-136, using phage 80α (eryth-
romycinr). A sarA deletion in strains JE2 and 300-169 was
achieved by transducing the sarA::kan mutation from
ALC2543 (COL with a sarA::kan mutation) [15], using phage
85 (kanamycinr). The study MRSA strains were routinely
grown in tryptic soy broth or on tryptic soy agar.
Determination of Vancomycin MICs
MICs for vancomycin were determined by the standard broth
microdilution method, as recommended by the Clinical and
Laboratory Standards Institute [20].
In Vitro Time-Kill Curve of Vancomycin
The bactericidal activities of vancomycin (range, 1–5 ×MICs)
were compared between the parental strains and their respective
sarA mutants by use of killing curve analyses [21].
Population Analyses Assay
Vancomycin population analyses were performed by standard
protocols [22]. The range of vancomycin concentrations tested
was 0.125–16 μg/mL to encompass sublethal-to-lethal drug
levels, using an initial inoculum of approximately 109 colony-
forming units (CFU)/mL. Population analysis curves were com-
pared between each strain pair [8].
Bioﬁlm Formation
Bioﬁlm formation of the study MRSA strains was performed
under static conditions [8, 23]. Brieﬂy, MRSA cells from fresh
culture plates were adjusted to a density of 0.5 McFarland stan-
dard and diluted 1:100 into brain heart infusion broth supple-
mented with 0.5% glucose; 200 μL of this suspension was
transferred to 96-well tissue culture plates and incubated for
18 hours at 37°C. After incubation, the wells were washed, air
dried, and stained with safranin (0.1% in distilled water). The
adhering dye was dissolved in 30% acetic acid, and absorption
was measured at OD490nm to quantify bioﬁlm formation [8, 23].
Numerous investigations have shown that sub-MICs of some
antibiotics can induce bacterial bioﬁlm formation [8, 10, 24]. In
this regard, we have recently reported that exposure to sub-
MICs of vancomycin can promote MRSA bioﬁlm formation,
a process that may have clinical signiﬁcance [8]. Therefore,
the above static bioﬁlm formation assay was performed in par-
allel with exposure to 0.5 times the MIC of vancomycin.
Bioﬁlm Stability
Bacterial bioﬁlms consist of carbohydrates, proteins, and extra-
cellular DNA in variable proportions [9, 23]. Distinct bioﬁlm
chemical compositions are felt to contribute functionally and
structurally to the organization of bioﬁlm [9]. Therefore,
Table 1. Staphylococcus aureus Strains Used in This Study
Strains Relevant Characteristic(s) Reference
ALC637 Newman sarA:Tn917LTV1, ermR [14]
ALC2543 COL sarA::kan [15]
300-169 HA-MRSA (patient with persistent
bacteremia)
[16]
300-169 ΔsarA 300-169 sarA::kan This study
324-136 HA-MRSA (patient with persistent
bacteremia)
[16]
324-136 ΔsarA 324-136 sarA::Tn917LTV1 This study
MW2 CA-MRSA, USA400 [15]
ALC5415 MW2 sarA::kan [15]
JE2 CA-MRSA, LAC, USA300 [17]
JE2 ΔsarA JE2 sarA::kan This study
Abbreviations: CA-MRSA, community-acquired methicillin-resistant S. aureus;
HA-MRSA, healthcare-associated methicillin-resistant S. aureus.
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differences in the stability of MRSA bioﬁlm as a function of spe-
ciﬁc biochemical components were separately assessed in the
presence of carbohydrate, protein, or DNA dispersal agents
[23]. The supernatants of 18-hours-old bioﬁlms generated by
the study MRSA strains were replaced by fresh medium supple-
mented with either 10 mM sodium metaperiodate, 100 μg/mL
proteinase K, or 140 U/mL RNase-free DNase I to assess relative
carbohydrate, protein, and DNA content, respectively [23]. All
incubations were performed for 2 hours at 37°C. Media without
the above supplements served as respective controls. After treat-
ment, the bioﬁlms were quantiﬁed as described above.
Autolysis Assay
Standard Triton X-100–induced autolysis was performed as
described elsewhere [15]. In addition, it has been reported that
increased staphylococcal autolysis mediated by exposure to sub-
MICs of vancomycin exposure can augment bioﬁlm formation
[10]. Thus, the MRSA strains were also examined for vancomy-
cin-induced lysis. In brief, overnight cultured strains were adjust-
ed to an OD580nm of 0.7, washed, exposed to 50 mM Tris-HCl
(pH 7.2) containing either 0.05% Triton X-100 or 0.5 times the
MIC of vancomycin, and incubated at 30°C with agitation (200
rpm). Staphylococcal lysis was measured during 24 hours of in-
cubation by determining the changes in OD580nm.
Adherence to Fibronectin
For these assays, 6-well tissue culture plates were coated with
puriﬁed human ﬁbronectin (50 μg/mL) for 18 hours and then
treated with 3% bovine serum albumin for 3 hours to prevent
nonspeciﬁc adhesion [25]. Overnight-cultured MRSA cells
grown in the presence or absence of 0.5 times the MIC of van-
comycin were added to the plates (5×103 CFU) and incubated
for 1 hour [25]. Wells were then washed, and tryptic soy agar
were added to each well, and overnight incubation at 37°C
was performed. Adherence was expressed as the percentage
(±SD) of the initial inoculum bound.
Protease and Nuclease Activity
MRSA extracellular proteases and nucleases are essential modu-
lators of bioﬁlms, being involved in the degradation of the
bioﬁlm matrix; they may also play a critical role in the bioﬁlm-
deﬁcient phenotype in the sarA mutants [9, 26, 27]. Therefore,
we tested overall extracellular protease and nuclease production
of the study strains, using 1% caseinate agar (for proteolysis ac-
tivity) and DNase agar (for nuclease activity) plates in the pres-
ence or absence of 0.5 times the MIC of vancomycin [27, 28].
Rabbit Model of MRSA Infective Endocarditis
A well-characterized rabbit model of catheter-induced aortic
valve infective endocarditis with intravenous injection of ap-
proximately 105 CFU of each MRSA strain was used [16]. Rab-
bits were maintained in accordance with the American
Association for Accreditation of Laboratory Animal Care
criteria. The Institutional Animal Care and Use Committee of
the Los Angeles Biomedical Research Institute at Harbor-UCLA
Medical Center approved all animal study protocols. Twenty-
four hours after infection, animals were randomized to receive
no therapy (controls) or vancomycin (15 mg/kg or 7.5 mg/kg)
intravenously twice daily for 3 days for HA- and CA-MRSA
strain sets, respectively. Twenty-four hours after the last vanco-
mycin dose, animals were euthanized, and their cardiac vegeta-
tions, kidneys, and spleen were removed and quantitatively
cultured [16]. MRSA counts in target tissue are given as the
mean log10 CFU/g of tissue (±SD).
Assessment of sarA Transcriptions In Vitro and Within Cardiac
Vegetations In Vivo by Real-Time Quantitative PCR (qPCR)
For sarA transcriptions in vitro, RNAwas isolated from cultures
that were grown for 24 hours with or without exposure to 0.5
times the MIC of vancomycin for comparison with data gener-
ated in vivo within cardiac vegetation samples collected 24
hours after infection (see below) [16]. Brieﬂy, 2 μg of DNase-
treated RNA was transcribed into complementary DNA [16].
Real-time qPCR was performed using an ABI Prism 7000 in-
strument (Applied Biosystems) and the SYBR green PCR mas-
ter kit (Applied Biosystems). The primers used to amplify sarA
were qRT-sarA-F (5′-TCTTGTTAATGCACAACAACGTAA-
3′) and qRT-sarA-R (5′-TGTTTGCTTCAGTGATTCGTTT-
3′). gyrB was used to normalize for transcript quantiﬁcation
[16].Relative quantiﬁcation was calculated by the ΔΔCT method
[29]. PCR experiments were performed using 2 biological rep-
licates, each tested in triplicate.
For quantifying sarA transcripts within cardiac vegetations,
catheterized animals were infected with each parental strain as
described above. Twenty-four hours after infection, animals
were randomized to receive no therapy or vancomycin as de-
scribed above. Vancomycin was given for 1 day only (to ensure
adequate numbers of MRSA cells within cardiac vegetations for
RNA extractions). Twenty-four hours after receipt of the last
vancomycin dose, animals were euthanized, and their cardiac
vegetations were quick-frozen in liquid nitrogen. Total RNA
was isolated using Tri reagent (Ambion) according to the man-
ufacturer’s instructions, including a 0.635 cm ceramic sphere in
the cell disruption step [16]. Samples were then processed as de-
scribed above. Real-time qPCR analysis for sarA expression was
performed on at least 3 different animals for each group.
RESULTS
Vancomycin MICs
Vancomycin MICs were 0.5 μg/mL for the 2 HA-MRSA strains
and 1.0 and 2.0 μg/mL for CA-MRSA strains MW2 and JE2, re-
spectively. In addition, no differences were detected in vanco-
mycin MICs between the parental strains and their respective
sarA mutant strains.
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In Vitro Time-Kill Curve of Vancomycin
The results of the in vitro time-kill curve analysis of vancomycin
are shown in Figure 1. No signiﬁcant differences in vancomycin
bactericidal effects were observed between parental and sarA
mutant strains. In addition, no strains exhibited in vitro toler-
ance to exposure to 5 times the MIC of vancomycin (Figure 1).
Figure 1. In vitro time-kill curves of vancomycin against healthcare-associated methicillin-resistant Staphylococcus aureus (HA-MRSA; 300–169 and
324–136; A) and community-acquired MRSA (CA-MRSA; MW2 and JE2; B) strain sets. ▪, control; ⋄, 1 times the minimum inhibitory concentration (MIC) of
vancomycin; Δ, 2 times the MIC of vancomycin; ✱, 5 times the MIC of vancomycin.
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Population Analyses
None of the study isolates revealed vancomycin-heteroresistant
subpopulations (data not shown). In addition, there were no
population curve shifts in comparing the parent and sarA mu-
tant strains within each strain pair.
Bioﬁlm Formation Under Static Conditions
Consistent with previous reports [11, 12], all 4 sarA mutation
were defective in bioﬁlm formation as compared to their re-
spective parental strains (Figure 2A). Interestingly, sublethal
levels of vancomycin (ie, 0.5 times the MIC) signiﬁcantly pro-
moted bioﬁlm formation in both HA-MRSA parental strains
and in CA-MRSA parental strain JE2, compared with their re-
spective parental controls without vancomycin exposure (Fig-
ure 2B). However, vancomycin exposure did not signiﬁcantly
change the bioﬁlm formation proﬁle in the MW2 parental
strain (Figure 2B). Importantly, sublethal vancomycin expo-
sure did not induce bioﬁlm formation in any of the sarA
mutants.
Bioﬁlm Stability
Treatment with sodium metaperiodate, proteinase K, or DNase
I led to a similar signiﬁcant reduction of bioﬁlm formation in
the 2 HA-MRSA parental strains, compared with their respec-
tive controls without exposure to any dispersal agent (Sup-
plementary Figure 1). However, treatment with sodium
metaperiodate did not cause a signiﬁcant reduction of bioﬁlm
formation in 2 CA-MRSA parental strains, compared with
their respective controls without sodium metaperiodate expo-
sure, suggesting that bioﬁlm formed by these CA-MRSA
strains might have relatively lower carbohydrate content (com-
pared with levels of protein and DNA; Supplementary
Figure 1). For all sarA mutants, treatment with sodium meta-
periodate had little effect on bioﬁlm stability, whereas there was
signiﬁcant bioﬁlm dispersion by treatment with proteinase K
and DNase in 2 of the 4 sarA mutants, suggesting that these
2 sarA mutant strains have less carbohydrate content, com-
pared with protein and DNA content (Supplementary
Figure 1).
Figure 2. Impact of sarA on bioﬁlm formation. A, Bioﬁlm formation of the wild types and their isogenic sarA mutants was quantiﬁed using a microtiter
plate assay by solubilizing the safranin in 30% acetic acid, and absorption was measured at 490 nm. Results are shown as the mean of the A490nm ± SD from
3 independent experiments, each of which was done in triplicate. *P < .005 and **P < .0005 for the sarA mutants, compared with their respective parental
strain. B, Effect of 0.5 times the MIC of vancomycin (VAN) on bioﬁlm formation. Bioﬁlm formation without VAN exposure was deﬁned as being A490nm 1.0
and is represented by the dashed line. ▪, parental; □, sarA mutant. *P < .05, compared with control without VAN exposure.
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Cell Autolysis
No differences in autolysis proﬁles were observed between pa-
rental and sarA mutant strains in the presence of either Triton
X-100 or 0.5 times the MIC of vancomycin (data not shown).
Adherence to Fibronectin
As anticipated from prior studies [25, 30], inactivation of sarA
led to signiﬁcantly reduced ﬁbronectin binding in mutant
strains, compared with their respective parental strain (P < .05;
Figure 3A). Interestingly, in the presence of 0.5 times the MIC
of vancomycin, 2 HA-MRSA parental strains showed signiﬁ-
cantly increased binding to ﬁbronectin, compared with their re-
spective controls, whereas the 2 CA-MRSA strains exhibited
decreased ﬁbronectin binding (although this did not reach stat-
istical signiﬁcance; Figure 3B). For all sarAmutants, ﬁbronectin
binding did not increase with vancomycin exposure (Figure 3B).
Protease and Nuclease Activity
In accordance with previous studies showing that sarA negative-
ly regulates protease and nuclease gene expression [12], the sarA
mutants demonstrated increases in proteases and nuclease ac-
tivity in all study strains except strain JE2 (in which nuclease
activity did not change; Figure 4). Of note, although sub-
MICs of vancomycin had a positive impact on bioﬁlm forma-
tion as documented above, there were no differences in either
protease or nuclease production induced by vancomycin
(Figure 4).
Experimental Infective Endocarditis
At the 105 CFU challenge inoculum, 3 of the 4 sarA mutants
(excluding JE2) exhibited reduced virulence, compared with
their parental strains, in terms of MRSA densities achieved
within cardiac vegetations (but not kidneys or spleen; P < .05;
Figure 5). Of note, vancomycin treatment resulted in dramatic
and signiﬁcant reductions of MRSA counts in all target tissues
in animals infected with the sarA mutant strains (3.8–6.6 log10
CFU/g tissue reduction; P < .0005, compared with data for un-
treated sarAmutant controls; Figure 5). In addition, vancomycin
treatment resulted in approximately 80% culture negativity for
all target tissues among animals infected with sarA mutants in
300-169 and 324-136 strain backgrounds; also 18% and 100%
of organ cultures were sterile in animals infected with sarA mu-
tant in MW2 and JE2 backgrounds, respectively. In contrast, rab-
bits infected with 3 of the 4 parental strains (the 2 HA-MRSA
strains and the MW2 strain, but not the JE2 strain) did not re-
spond to vancomycin treatment, with residual target tissue
MRSA densities in vancomycin-treated animals being similar
to those in their respective untreated control groups (Figure 5).
sarA Transcriptions In Vitro and Within Cardiac Vegetations
On exposure to 0.5 times the MIC of vancomycin in vitro, all
parental strains exhibited signiﬁcantly higher sarA transcript
levels than those in their respective controls in the absence of
vancomycin exposure (Figure 6A). For sarA expression within
cardiac vegetations, higher sarA expression proﬁles were ob-
served in the vancomycin treatment groups, compared with
their respective controls without vancomycin therapy (Fig-
ure 6B). Interestingly, higher sarA expression was detected in
Figure 3. Adherence of the study methicillin-resistant Staphylococcus
aureus (MRSA) strain sets to immobilized human ﬁbronectin in the absence
(A) or presence (B) of 0.5 times the minimum inhibitory concentration of
vancomycin (VAN). Controls without VAN exposure set up 100% adherence
to ﬁbronectin (B). ▪, parental strain; □, sarA mutant. *P < .05, compared
with their respective parental strain (A) or with controls without VAN ex-
posure (B ).
Figure 4. Production of extracellular protease and nuclease by the study
strain sets in the absence or presence of 0.5 times the minimum inhibitory
concentration of vancomycin (VAN). Results were assessed after overnight
incubation of the study strains on caseinate and DNase agar plates for pro-
tease and nuclease, respectively. P, parental strain; S, sarA mutant strain.
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HA-MRSA versus CA-MRSA parental strains without vanco-
mycin treatment. However, these differences did not reach stat-
istical signiﬁcance (Figure 6B).
DISCUSSION
Bioﬁlm formation is considered to be a major virulence factor in
many S. aureus syndromes, including infective endocarditis [9,
26]. Bioﬁlm formation not only facilitates bacterial colonization
of host tissues, but also fosters resistance to bacterial clearance
mediated by antimicrobial agents and by host immune responses
[9, 26]. In addition, bioﬁlms can serve as chronic foci of infection
for metastatic spread of bacteria and release of toxins into the
bloodstream, resulting in signiﬁcant morbidity and mortality
[9]. Therefore, bioﬁlm formation has become a key target for
the development of novel therapeutic tools against these life-
threatening infections. In this study, we investigated the
Figure 5. Methicillin-resistant Staphylococcus aureus (MRSA) densities in target tissues in the infective endocarditis model, with or without vancomycin
(VAN) treatment (15 mg/kg and 7.5 mg/kg intravenously twice daily for 3 days for healthcare-associated MRSA [A] and community-acquired MRSA [B]
strains, respectively). Each dot represents 1 rabbit. Horizontal black bars indicate mean values of observations.
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modulation of a central regulatory element that controls the pro-
duction of many S. aureus virulence factors (including bioﬁlm),
sarA, as means of enhancing antimicrobial efﬁcacy in a proto-
typical MRSA bioﬁlm infection model (infective endocarditis).
In the current investigation, consistent with other reports, we
observed that sarA mutants formed signiﬁcantly less bioﬁlm in
vitro in all study strains, compared with their respective parental
strains [11, 12]. It is well known that sarA has a global effect on
many S. aureus virulence genes that seem to play a role in bio-
ﬁlm formation (eg, multiple extracellular proteases, nuclease,
and ﬁbronectin-binding proteins [FnBPs]) [31]. For instance,
recent studies and our own current data show that the overall
production of extracellular proteases is increased in sarA mu-
tants, which may contribute to the reduced bioﬁlm phenotype
in such strains [27, 32, 33]. In addition, there is growing
evidence that the release of extracellular DNA from bacterial
cells undergoing autolysis during programmed cell death con-
tributes to bioﬁlm development [34, 35]. Therefore, an in-
creased production of extracellular nuclease may contribute to
the bioﬁlm-deﬁcient phenotype of sarAmutants [35, 36].More-
over, nuclease (nuc) mutants form a very thick bioﬁlm contain-
ing increased levels of matrix-associated extracellular DNA
[34]. In this regard, in the current study, 3 of our 4 sarAmutants
exhibited increased extracellular nuclease production, again
correlating with reduced bioﬁlm formation. Taken together,
these results suggest that the regulatory role of sarA in repress-
ing the production of extracellular enzymes (including proteas-
es and nucleases) is one key factor leading to bioﬁlm formation
and stability [27].
S. aureus bioﬁlm matrices consist of proteins, DNA, and
polysaccharide (also called the polysaccharide intercellular ad-
hesion [PIA] or poly-N-acetylglucosamine material) [9, 23]. Re-
cently, it has become evident that the presence of PIA is not
essential for bioﬁlm development in many MRSA strains [30].
Interestingly, in these PIA-independent bioﬁlms, FnBPs appear
to substitute for PIA in driving bioﬁlm formation [30]. In addi-
tion, this FnBP-mediated bioﬁlm seems to be particularly fre-
quent among highly virulent MRSA isolates, suggesting the
importance of PIA-independent bioﬁlm formation in such
strains [30]. SarA is a positive regulator of FnBP produc-
tion and subsequent bioﬁlm formation in 2 complementary
ways: (1) by enhancement of fnb gene expression and (2) by
repression of extracellular proteases, which normally cleave
and remodel surface adhesins such as FnBP [12, 13]. Thus, we
tested the ﬁbronectin-binding capacities of our study strains.
Our results, in agreement with other studies [25, 37], found
that all sarA mutants had signiﬁcantly decreased capacity to
bind to ﬁbronectin. This reduced ﬁbronectin-binding pheno-
type was correlated with increased protease production ob-
served in sarA mutants, ostensibly contributing to reduced
bacterial colonization at the early steps of endovascular
infection.
Several groups have shown that sub-MICs of selected antibi-
otics, including vancomycin, can promote S. aureus bioﬁlm for-
mation in vitro [10, 38, 39]. In the current studies, we applied
this concept to characterize the impact of sub-MICs of vanco-
mycin on sarA-mediated bioﬁlm formation in a model of per-
sistent endovascular infection due to HA- and CA-MRSA
strains. Vancomycin was chosen in this investigation because
it remains a clinical mainstay as an anti-MRSA agent. We con-
ﬁrmed that sub-MICs of vancomycin signiﬁcantly promoted bi-
oﬁlm formation in 3 of 4 MRSA parental strains (excluding
MW2). In contrast, all sarA mutants demonstrated reduced bi-
oﬁlm formation in the presence or absence of sub-MICs of van-
comycin in vitro. In addition, we demonstrated that sub-MICs
of vancomycin signiﬁcantly increased sarA gene expression in
all study parental strains studied in vitro, compared with their
Figure 6. Expression of sarA in all study methicillin-resistant Staphylo-
coccus aureus (MRSA), parental strain with (+) or without (−) exposure in
vitro to 0.5 times the minimum inhibitory concentration of vancomycin
(VAN) exposure, after 24 hours (A) and within infected cardiac vegetations,
with or without exposure to VAN, in the infective endocarditis model 24
hours after infection (B). Data were obtained by real-time quantitative po-
lymerase chain reaction. Relative transcript levels of sarA represent the
mean (+SD) of 2 biological replicates in vitro and of at least 3 animals
per group in vivo (fold-changes vs gyrB). *P < .05 and **P < .005, compared
with their respective controls without VAN exposure in vitro.
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respective controls without vancomycin exposure. This out-
come was mirrored in vivo, because vancomycin treatment re-
sulted a trend toward higher MRSA sarA expression within
infective endocarditis cardiac vegetations, compared with ﬁnd-
ings for respective controls without vancomycin therapy. These
phenotypic and genotypic differences in the impact of sub-
MICs of vancomycin on bioﬁlm formation and sarA expression
paralleled in vivo outcomes. Thus, animals infected with paren-
tal MRSA strains were resistant to vancomycin treatment,
whereas animals infected with sarA mutants were exquisitely
susceptible to vancomycin therapy in the infective endocarditis
model.
We recognize that additional mechanisms likely contribute to
the differences in vancomycin-associated outcomes in vivo as
noted above. For example, vancomycin has limited and slow
penetration into bioﬁlms [40, 41]. Therefore, one intriguing
possibility is that sarAmutant strains form signiﬁcantly thinner
and/or less well-structured bioﬁlms in vivo, compared with
their respective parental strains. In turn, this latter phenotype
may conceivably allow greater penetration of vancomycin into
such defective bioﬁlms. Furthermore, Hsu et al [10] reported
that sublethal doses of vancomycin can induce more-robust bi-
oﬁlm formation through an enhanced autolysis- and extracellu-
lar DNA–dependent release in S. aureus. In contrast to their
ﬁndings, however, the present studies were unable to detect
any impact of sub-MICs of vancomycin on either autolysis or
nuclease or protease production, suggesting these latter mecha-
nisms were not in play in the current study strains.
Last, we noted that mutations in sarA had a deﬁnable, albeit
modest effect on innate MRSA virulence, being observed only
with in cardiac vegetations. This impact of sarA on infective en-
docarditis pathogenesis has been seen in prior studies in this
model, using other S. aureus strains [6, 25, 42]. Of major impor-
tance, vancomycin therapy in the experimental infective endo-
carditis model was able to divulge the ability of sarA to blunt
antimicrobial efﬁcacies, presumably via a bioﬁlm-dependent
pathway. Interestingly, these in vivo results were observed de-
spite similar vancomycin MICs and in vitro vancomycin killing
kinetics between sarA mutants and their respective parental
strains. These results suggest that sarA plays a key role in endo-
vascular infections, especially in terms of antimicrobial therapy
responsiveness, likely, at least in part, because of the decreased
production of extracellular protease, resulting in augmented bi-
oﬁlm formation.
In summary, the present ﬁndings are, to our knowledge, the
ﬁrst to reveal the importance of sarA in 2 critical aspects of
S. aureus pathogenesis in endovascular infections caused by
clinical isolates: bioﬁlm formation and target tissue persistence.
Although the mechanism(s) of these phenomena are not entire-
ly deﬁned, these data support the notion that suppression of
SarA has therapeutic potential in the important context of bio-
ﬁlm-associated infections due to HA-MRSA and CA-MRSA.
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